BCR and monocytic leukemia: Hydralazine has been demonstrated to reduce the viability of monocytic leukemia cells [52] and to counteract chemoresistance in chronic myeloid leukemia [53], a clonal disorder associated with the Philadelphia chromosome, which results from the t(9;22) translocation and carries the BCR-ABL fusion gene that encodes the oncogenic BCR-ABL protein.